Proton beam radiation therapy for head and neck malignancies.

Abstract:

:Proton beam radiation therapy (PBRT) has unique physical properties (e.g., Bragg Peak) that limit the amount of normal tissue irradiated in the head and neck region while maximizing the radiation delivered to the tumor. Radiation therapy is commonly used in both the primary and adjuvant setting for many head and neck malignancies. Limiting the unnecessary radiation to normal tissues within the head and neck region can result in a profound improvement in quality of life during and after treatment. Although PBRT was initially developed in the 1950s, recent technological advances have permitted the development of hospital-based facilities for proton delivery. PBRT has been shown to improve outcomes for patients with sinonasal tumors, chordomas, chondrosarcomas, ocular, and periocular malignancies. Further development of intensity-modulated proton therapy will permit comprehensive treatment for head and neck tumors.

journal_name

Curr Oncol Rep

journal_title

Current oncology reports

authors

Frank SJ,Selek U

doi

10.1007/s11912-010-0089-0

subject

Has Abstract

pub_date

2010-05-01 00:00:00

pages

202-7

issue

3

eissn

1523-3790

issn

1534-6269

journal_volume

12

pub_type

杂志文章,评审
  • Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway.

    abstract::Gastrointestinal stromal tumors (GISTs) are the most common soft tissue sarcoma, and most feature abnormalities in two genes encoding the receptor tyrosine kinases (RTKs), KIT, and PDGFRA. The RTK inhibitor imatinib revolutionized treatment in GIST; however, drug resistance remains a challenge. Constitutive autophosph...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-013-0316-6

    authors: Patel S

    更新日期:2013-08-01 00:00:00

  • Neoadjuvant therapy for breast cancer: assessing treatment progress and managing poor responders.

    abstract::There is no clear consensus regarding the most effective management of poor responders to neoadjuvant chemotherapy. Intensifying or changing primary systemic treatment has not been shown to offer any benefit. There is a paucity of trials testing the utility of adjuvant chemotherapy in this setting. Adjuvant hormonal t...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-009-0007-5

    authors: Wesolowski R,Budd GT

    更新日期:2009-01-01 00:00:00

  • Preoperative and adjuvant treatment of localized rectal cancer.

    abstract::Although postoperative chemoradiation has a proven role in the treatment of stage II to III localized rectal cancer, recent trials have demonstrated the role of preoperative chemoradiation. A recent randomized trial has shown that preoperative chemoradiation yields higher rates of local control and sphincter preservat...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-006-0016-6

    authors: Das P,Crane CH

    更新日期:2006-05-01 00:00:00

  • Guiding Treatment Choices for Elderly Patients with Glioblastoma by a Comprehensive Geriatric Assessment.

    abstract:PURPOSE OF REVIEW:The incidence of glioblastoma multiforme (GBM) increases with age; more than half of newly diagnosed patients are older than 65 years. Due to age-dependent decreasing organ functions, comorbidities, functional decline, and increasing risk of social isolation, not all patients are able to tolerate stan...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-020-00951-6

    authors: Lütgendorf-Caucig C,Freyschlag C,Masel EK,Marosi C

    更新日期:2020-07-10 00:00:00

  • MEK inhibition in the treatment of advanced melanoma.

    abstract::The RAS-RAF-MEK-ERK pathway is considered to be the most important signal transduction pathway in melanoma, and alterations in this pathway via various genetic mutations, such as BRAF and NRAS mutations, are known to be important drivers of melanomagenesis. As MEK is an essential intermediary kinase protein within thi...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-013-0336-2

    authors: Salama AK,Kim KB

    更新日期:2013-10-01 00:00:00

  • Postmastectomy radiotherapy in intermediate-risk patients: the gray zone.

    abstract::Postmastectomy radiotherapy continues to be one of the most controversial issues in breast radiotherapy. At the crux of the controversy lies the lack of conclusive studies that specifically address the risk-benefit ratio of postmastectomy radiotherapy for patients at intermediate risk of developing locoregional recurr...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-006-0006-8

    authors: Sartor CI

    更新日期:2006-01-01 00:00:00

  • VEGF inhibition, hypertension, and renal toxicity.

    abstract::The use of anti-angiogenic agents as part of the therapeutic armamentarium for advanced stage solid tumors has become the standard of care in several instances, particularly for renal cell carcinoma, non-small cell lung carcinoma, colorectal carcinoma, and gastrointestinal stromal tumors. These agents primarily target...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-012-0242-z

    authors: Hayman SR,Leung N,Grande JP,Garovic VD

    更新日期:2012-08-01 00:00:00

  • Interventions that Facilitate Shared Decision-Making in Cancers with Active Surveillance as Treatment Option: a Systematic Review of Literature.

    abstract:PURPOSE OF REVIEW:Medical decisions concerning active surveillance are complex, especially when evidence on superiority of one of the treatments is lacking. Decision aids have been developed to facilitate shared decision-making on whether to pursue an active surveillance strategy. However, it is unclear how these decis...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-020-00962-3

    authors: Collée GE,van der Wilk BJ,van Lanschot JJB,Busschbach JJ,Timmermans L,Lagarde SM,Kranenburg LW

    更新日期:2020-07-28 00:00:00

  • Particle Radiation Therapy for Gastrointestinal Cancers.

    abstract::Particle irradiation of cancerous disease has gained great traction in recent years. The ability for particle therapy centers to deliver radiation with a highly conformal dose distribution while maintaining minimal exit or excess dose delivered to normal tissue, coupled with various biological advantages particularly ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-016-0499-8

    authors: Shinoto M,Ebner DK,Yamada S

    更新日期:2016-03-01 00:00:00

  • Correction to: Systemic Therapy of Central Nervous System Metastases of Breast Cancer.

    abstract::The original version of this article, which published in Current Oncology Reports, Volume 21, Issue 6, June 2019, contained an error in addressing the indication for use of neratinib in early stage breast cancer. ...

    journal_title:Current oncology reports

    pub_type: 已发布勘误

    doi:10.1007/s11912-019-0813-3

    authors: Leone JP,Lin NU

    更新日期:2019-05-17 00:00:00

  • Intensity-modulated radiotherapy for carcinoma of the head and neck.

    abstract::Intensity-modulated radiotherapy (IMRT) is the next evolutionary step of three-dimensional conformal radiotherapy (3-DCRT). IMRT plans are generated with computer-optimized nonuniform radiation beam intensities incident on a target or patient. The dose distributions in IMRT show significantly higher conformality compa...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-003-0100-0

    authors: Peñagarícano JA,Papanikolaou N

    更新日期:2003-03-01 00:00:00

  • Targeting pediatric malignancies for T cell-mediated immune responses.

    abstract::Successful immune targeting of malignancies hinges upon the ability to activate specific T-cell populations to recognize and attack tumor but spare normal vital tissues. Investigators in the field of tumor immunology are currently utilizing at least three distinct approaches toward this goal. In the first approach, mo...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0108-7

    authors: Mackall CL,Helman LJ

    更新日期:2000-11-01 00:00:00

  • PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.

    abstract::The mammalian target of rapamycin (mTOR) and the phosphoinositide 3-kinase (PI3K) signaling pathways are commonly deregulated in cancers and promote cellular growth, proliferation, and survival. mTOR is part of two complexes, mTORC1 and mTORC2, with different biochemical structures and substrates specificity. PI3K/AKT...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-012-0227-y

    authors: Willems L,Tamburini J,Chapuis N,Lacombe C,Mayeux P,Bouscary D

    更新日期:2012-04-01 00:00:00

  • Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.

    abstract:PURPOSE OF REVIEW:Patients with cancer have an elevated risk of cardiovascular disease. This review describes the cardiovascular risks of different cancer therapies and the evidence for cardioprotective strategies. RECENT FINDINGS:Recent studies have provided additional support for the safety and efficacy of dexrazoxa...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-020-00923-w

    authors: Upshaw JN

    更新日期:2020-06-20 00:00:00

  • Chemotherapy for androgen- independent prostate cancer: myth or reality.

    abstract::In the past, the treatment options for patients with metastatic prostate cancer that progressed despite castrate levels of testosterone was limited, and no therapies provided an improvement in survival. The majority of these patients had extensive osseous disease, multiple comorbidities, and poor performance status. W...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-000-0058-0

    authors: Kelly WK,Slovin SF

    更新日期:2000-09-01 00:00:00

  • Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors.

    abstract:PURPOSE OF REVIEW:Immune checkpoint inhibitors (ICI) are only effective in a subset of patients. Here, we will review the rationale and data supporting the combination of PD-1 pathway inhibition with recombinant cytokines and neoantigen-based cancer vaccines that can potentially increase the number of patients who will...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-018-0738-2

    authors: Barroso-Sousa R,Ott PA

    更新日期:2018-11-15 00:00:00

  • Review of neoadjuvant chemotherapy and trachelectomy: which cervical cancer patients would be suitable for neoadjuvant chemotherapy followed by fertility-sparing surgery?

    abstract::The number of patients given neoadjuvant chemotherapy (NAC) followed by fertility-sparing surgery in cervical cancer is still scarce. Only a few centres perform these procedures, and thus, such procedures remain largely in the experimental stage. Patients that do not fulfil the criteria for standard fertility-sparing ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-015-0446-0

    authors: Robova H,Rob L,Halaska MJ,Pluta M,Skapa P

    更新日期:2015-01-01 00:00:00

  • Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?

    abstract:PURPOSE OF REVIEW:Anaplastic lymphoma kinase (ALK) rearrangements represent a seldom event in non-small cell lung cancer (NSCLC). Given the oncogene alteration, ALK targeting represents the main therapeutic strategy. Here, we review evidence regarding ALK inhibitors (ALKi): clinical activity, safety profiles, financial...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-020-00989-6

    authors: Tabbò F,Passiglia F,Novello S

    更新日期:2021-01-02 00:00:00

  • The development of VAC chemotherapy in rhabdomyosarcoma: what does one do for an encore?

    abstract::The establishment of the Intergroup Rhabdomyosarcoma Study (IRS) Committee in 1972 by three extant American pediatric cooperative groups initiated five generations of studies in the multidisciplinary treatment of soft-tissue sarcomas. Taking the lead from the use of vincristine, actinomycin-D, and cyclophosphamide (VA...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-003-0012-z

    authors: Ruymann FB

    更新日期:2003-11-01 00:00:00

  • Value and Quality of Care in Head and Neck Oncology.

    abstract:PURPOSE OF REVIEW:The concept of value-based health care (VBHC) was articulated more than a decade ago. However, its clinical implementation remains an on-going process and a particularly demanding one for the domain of head and neck cancer (HNC). These cancers often present with fast growing tumors in functionally and...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-020-00952-5

    authors: Takes RP,Halmos GB,Ridge JA,Bossi P,Merkx MAW,Rinaldo A,Sanabria A,Smeele LE,Mäkitie AA,Ferlito A

    更新日期:2020-07-10 00:00:00

  • Osteoporosis in women with breast cancer.

    abstract::Osteoporosis is a disease that causes substantial morbidity and mortality for which preventive therapy is available. Women with breast cancer are at increased risk for osteoporosis for several reasons, including premature ovarian failure as a result of treatment, direct effects of chemotherapy, and effects of the brea...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-003-0086-7

    authors: Mincey BA

    更新日期:2003-01-01 00:00:00

  • Current and future strategies for combined-modality therapy in pancreatic cancer.

    abstract::Treatment of pancreatic cancer remains a challenging task that often requires a multidisciplinary approach to confer optimal response and, ideally, maximize survival. A combination of locoregional approaches such as surgery and radiotherapy, along with systemic therapies for eradication of micrometastases, should be c...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-002-0017-z

    authors: Ko AH,Tempero MA

    更新日期:2002-05-01 00:00:00

  • Radical surgery in ovarian cancer.

    abstract::While there is an ongoing debate regarding the timing of the maximal surgical effort in epithelial ovarian cancer, it is well established that patients with suboptimal tumor debulking derive no benefit from the surgical procedure. The amount of residual disease after cytoreductive surgery has been repeatedly identifie...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-015-0439-z

    authors: Narasimhulu DM,Khoury-Collado F,Chi DS

    更新日期:2015-04-01 00:00:00

  • Early Cervical Cancer: Current Dilemmas of Staging and Surgery.

    abstract:PURPOSE OF REVIEW:Advances in cervical cancer screening and treatment have resulted in high cure rates in developed countries for early-stage disease. Current research focuses on minimizing morbidity and maximizing quality of life. RECENT FINDINGS:Imaging has been disappointing in identifying small volume metastases. ...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-017-0614-5

    authors: Zigras T,Lennox G,Willows K,Covens A

    更新日期:2017-08-01 00:00:00

  • Treatment Strategy for Distant Synchronous Metastatic Head and Neck Squamous Cell Carcinoma.

    abstract:PURPOSE OF REVIEW:Management of metastatic head and neck squamous cell cancers (HNSCC) can be challenging. This review gives an insight of current treatment options for patients with synchronous metastatic HNSCC and suggests a therapeutic algorithm. RECENT FINDINGS:With the rise of novel therapeutic techniques and med...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-019-0856-5

    authors: Tang E,Lahmi L,Meillan N,Pietta G,Albert S,Maingon P

    更新日期:2019-11-14 00:00:00

  • Prostate cancer screening.

    abstract::Prostate cancer is the most common cancer and the second leading cause of cancer-related deaths in American men. Although the use of the prostate-specific antigen (PSA) test for prostate cancer screening since the 1990s has led to increased early diagnoses, the most recent studies are in conflict about the risks and b...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-010-0136-x

    authors: Cook ED,Nelson AC

    更新日期:2011-02-01 00:00:00

  • Postmastectomy radiation therapy.

    abstract::Many women undergo mastectomy as treatment of their breast cancer either because of personal preference or because of tumor-related factors making mastectomy the preferred surgical option. The use of postmastectomy radiation therapy has been shown to decrease the risk of local recurrence and in some cases improve over...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-013-0361-1

    authors: Lyons JA,Sherertz T

    更新日期:2014-01-01 00:00:00

  • Management of primary intraocular lymphoma.

    abstract::Primary intraocular lymphoma (PIOL) is a subset of primary central nervous system lymphoma (PCNSL) in which malignant lymphoid cells invade the retina, vitreous body, or optic nerve head. It is usually a large B-cell non-Hodgkin's lymphoma. PIOL typically presents as a vitritis that is unresponsive to corticosteroid t...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-005-0029-6

    authors: Kim SK,Chan CC,Wallace DJ

    更新日期:2005-01-01 00:00:00

  • Regorafenib (BAY 73-4506): stromal and oncogenic multikinase inhibitor with potential activity in renal cell carcinoma.

    abstract::The introduction of targeted therapies, specifically those that target the VEGF receptor (VEGFR), PDGF receptor (PDGFR) and the mTOR pathways, has significantly changed the approach to patients with unresectable renal cell cancer (RCC). However, drug resistance develops through bypassing of targeted pathways. Regorafe...

    journal_title:Current oncology reports

    pub_type: 杂志文章

    doi:10.1007/s11912-013-0292-x

    authors: Zaki K,Aslam S,Eisen T

    更新日期:2013-04-01 00:00:00

  • Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development.

    abstract:PURPOSE OF REVIEW:The aim of this review is to highlight the clinical development of PD-1 and PD-L1 inhibitors in cancer therapy. We focus on detailing the registration trials that have led to FDA-approved indications of anti-PD-1 and anti-PD-L1 therapies and future strategies. RECENT FINDINGS:The number of PD-1/PD-L1...

    journal_title:Current oncology reports

    pub_type: 杂志文章,评审

    doi:10.1007/s11912-020-00928-5

    authors: Oliveira LJC,Gongora ABL,Jardim DLF

    更新日期:2020-06-12 00:00:00